In this setting, AR gene amplification and overexpression enable tumors to respond to even minimal levels of androgens or weak agonists, while mutations in the receptor’s LBD, such as T877A or F876L, can convert certain anti-androgen factors into partial agonists that promote tumor growth [30]. The gene discussed is AR; the disease is neoplasm.